Hello everyone, and welcome. Today, we're here to talk about the future of benchtop sequencing and you, the researchers and scientists using our MiSeq system. Over the last ten years, some of the biggest discoveries and genomic insights have come from your benchtops while using this system. Throughout the years, your impactful work has grown and evolved. You've told us about the challenges that you and your lab face. You told us about your need for faster, simpler, and more affordable workflows to help run your lab more efficiently and stay competitive. And you told us that you want to see greener, more sustainable technology to reduce the environmental impact. A solution that has the speed to complete a run in a single shift instead of a few days. A solution that makes sequencing easier, even for the new users with limited lab experience.
You told us you want to expand the breadth of applications to drive more discoveries, all at a lower cost, and you said that reducing the time and space it takes to unpack and store reagents would be a game changer for your operations. Well, we heard you. To deliver this new solution, we took learnings from building the NovaSeq X Series from the ground up. The genomics ecosystem is large, and we wanted to bring the same simple workflows and fast insights to our benchtop community, and today, we are delighted to show you our newest reinvention.
Study infectious diseases. Analyze genomic variations in tumors. Project outbreaks through surveillance monitoring. Combat drug resistance. Discover mutations for disease control. Rapidly identify pathogens. Analyze RNA variants. [Audio distortion]
Simple. With breakthrough simplicity, our fastest runtimes yet, everything in one footprint with onboard DRAGEN analysis, and significant sustainability advancements. This is the highest standard in benchtop sequencing, empowering every lab everywhere on a quest for discoveries that can't wait. This is the MiSeq i100 Series. This is sequencing made simple.
I'm excited to introduce the MiSeq i100 Series, the most innovative and accessible benchtop sequencer that we've ever developed. With the complete end-to-end workflows across a broad range of applications, we are confident that the MiSeq i100 Series will allow you to further unlock the power of the genome in labs around the world. With this system, you'll now receive same-day results with high-quality data, simpler, streamlined operations, end-to-end workflows across many applications, and overall cost-efficient, sustainable solutions for your organization. All of us at Illumina are so excited to see what you can do with the MiSeq i100. Please welcome your host for the rest of the event, Everett Cunningham.
Thank you, Jacob. Hello, everyone, and welcome. My name is Everett Cunningham, and I'm the Chief Commercial Officer of Illumina. I will be your host today. Should you have any questions throughout the event, please enter them into the questions and answers box, and we'll get back to you following today's event. We'll take a closer look and introduce you to the MiSeq i100 Series and the speed and simplicity that it provides, in hopes that it will inspire your next great discovery. Throughout the event, labs across the world will share their experience with the MiSeq i100 and how they hope it will impact their research. We'll also highlight some of the innovations making the MiSeq i100 advancements possible and explore data from a few applications that demonstrate its exceptional performance.
I'm excited for you to hear from the Illumina scientists and engineers who worked hard on developing the MiSeq i100 Series to meet our customers' request. Now, speaking of customers, let's start with hearing the perspective of a few researchers who've been testing it in their labs.
So we were very excited to join this test of the new instrument, but we were actually positively surprised by all the possibilities we suddenly had. The turnaround time was great. The ease of use was much more than we expected. The shipment of the reagents at room temperature just gave us totally new possibilities in the lab, so I think this new machine will be a game changer on the market.
It's really amazing for us to be able to launch a run on the morning and have the result at the beginning of the afternoon. It's a really new paradigm for us because we are able to launch a full library prep in one day.
The new instrument has an increased output, so you can produce up to one hundred million reads. This basically gives us the same amount of data that you would get from a P1 flow cell on the NextSeq 1000. So you have a great breadth of number of samples you can do, and especially in microbial genomics, you can thereby sequence many, many more bacteria at the same time and process your bigger experiments and projects much more efficiently.
With the new equipment, we can have the same result, but with the good number of reads that the customer want, and in term of speed, it's really more efficient, because we can launch it on a day, and because the price of the cartridge, we can imagine having perhaps two new equipment or three new equipment, so it's really a new way to work in term of production, in term of dynamics, and at the end, in term of flexibility. Really easy. In five minutes, and less than five minutes, it's okay. We have the equipment, put it on a bench, turn on, and in just after installation, in one hour, we can launch the first run, so it's really simple.
It's very easy to use, also for the technicians. It's very easy to install. The reagents are shipped at room temperature, so you save money for storage and for the shipping. You reduce waste, and it's much faster, so you can do more in less time. When we tested the new instrument in the lab, we obviously also looked at data quality, and the data quality was as good or better as we expected. So, there's no downside to using the faster sequencing. You will get the same high-quality data that you're used to from Illumina.
It's wonderful to hear from users who have experienced the MiSeq i100 Series, and the impact they think it will have in their lab. Okay, who's ready to see the MiSeq i100? I'm happy to introduce Emmanuel Naouri, a product expert at Illumina. Hi, Emmanuel. Do you have something to show us?
I do, Everett. Hello, everyone. My name is Emmanuel Naouri. I have spent the last few years working with our R&D team, whose technical expertise is unmatched, to design this new system, and it is my pleasure to now present the MiSeq i100 Series. This system is packed with innovations to make sequencing faster, simpler, and more sustainable. But just how much? Let's dive into the details. First, its small footprint is perfect for any lab. This compact package comes in two different configurations: the MiSeq i100, with up to 25 million single-end reads per run, and the MiSeq i100 Plus, capable of generating up to 100 million single-end reads per run. Despite its compact size, it boasts incredible power. Thanks to XLEAP-SBS chemistry, it delivers massive improvements in both speed and accuracy, which we know are so vital to you.
The MiSeq i100 Series is nothing short of groundbreaking, offering fast, efficient operations for less hands-on time, making next-generation sequencing simpler than ever before. With the MiSeq i100 Series, the fluidics are integrated into the cartridge, meaning no more washes between runs. For those of you using MiSeq system today, that will save you almost two hours per run. A lot of innovation has been packed into these integrated cartridges, and you will hear Steve talk about it later. However, I want to highlight a couple key aspects now. First, denaturation now happens onboard, slashing hands-on time and increasing run-to-run consistency. Second, we removed hazardous chemicals, like formamide, to make disposal easier, and speaking of easy disposal, the cartridges are easy to disassemble. You don't even need any additional tools. With this instrument, we want to deliver efficient, reliable, and hassle-free sequencing every single time.
One other way we are doing that is with index first sequencing. This will be the first Illumina platform to offer this feature. With index first sequencing, you will receive your demultiplexing data without having to wait for your run to complete. Getting this analysis of the library pooling before the run finishes will save you time if additional runs need to be planned. The MiSeq i100 Series gives you flexibility. It provides an expanded output with multiple flow cells and cycle options. You can now produce data outputs of thirty gigabases and one hundred million reads, which is four times greater than the current MiSeq system. This increased output supports all the applications you're doing today, from amplicon sequencing to small RNA sequencing to microbial sequencing, allowing you to increase your discovery power.
This means you can run more samples, run larger panels, or sequence deeper than what was previously possible, and you will be able to do it faster than ever. Now, speaking of speed, we've dramatically decreased the runtimes with the MiSeq i100 Series. Due to current sequencing and run setup times, you told us you can only complete one single run per week per instrument. A typical run on the original MiSeq takes between 24 and 56 hours. That same run will take between four and sixteen hours on the MiSeq i100 Series. As an example, a three hundred cycle run with 25 million reads will be completed in under seven hours. Every run can be completed in a single day, with some runs taking only four hours. These improved runtimes can have a huge impact. Let me give you an example.
Several of you are performing community surveillance and need to identify pathogens as fast as possible to address an outbreak. The difference between one day and one week can be massive. We are also introducing game-changing features that will completely transform the way you sequence. Already a hit with NovaSeq X, room temperature shipping is now available on the MiSeq i100 Series. So no more ice packs and no more dry ice. Now, all your reagents arrive in a single small box. This results in 85% less packaging waste, and today, we are introducing room temperature consumable storage. This truly is revolutionary. You can now store reagents on a shelf, eliminating the need for freezers, saving space and energy. Regions with cold chain supply challenges will now have better access to sequencing.
The kits are ready for you, so you can grab them off the shelf and begin your run. With room temperature storage, thawing is a thing of the past. Imagine the freedom of sequencing on demand. Got an urgent sample? Just grab the cartridge, and you can start sequencing immediately. Of course, the most important part of sequencing is generating meaningful data. We know many NGS users struggle with the complexity of bioinformatics, so we have made it our mission to simplify it. The MiSeq i100 Series will have DRAGEN Secondary Analysis on board. With the DRAGEN license, including the purchase of an instrument, users will have access to our most comprehensive and accurate analysis pipelines. You can continue to leverage your current workflows or can access one of the 18 pre-designed sample-to-analysis workflows.
From small whole genome sequencing for microbiology to targeted panels for infectious disease and oncology, these push-button workflows are paired with pre-selected library kits and panels, helping to streamline experimental plannings. The workflows generate high-quality metrics two hours after the run for most applications, directly on the instrument, without the need for complex bioinformatics pipelines. With this instrument, you will receive seamless, powerful sequencing. I mean, there's so much to love about MiSeq i100 Series. You get the flexibility to do what you're doing today and more, and you can do it faster and easier, all while doing it more sustainably. And best of all, it unlocks applications that perhaps you haven't really thought you could do, from larger panels for targeted gene sequencing and transcriptomics to microbial genomics. We're so excited to bring this instrument to you, and we're even more excited to see what you will discover next.
Thanks, Emmanuel. Congratulations to you and the team on this important milestone. Now, to share all the work and innovation the team at Illumina did to bring MiSeq i100 to market, here's Steve Barnard, Illumina's Chief Technology Officer.
Thank you, Everett. On our journey to democratize NGS, we've established the industrial standard for benchtop sequencing with the MiSeq, bringing a powerful yet compact sequencer to our customers and enabling rapid results at a level of quality unmatched in the industry. The MiSeq has been a workhorse for scientific and clinical insights in oncology, research, molecular biology, and infectious disease. We are now redefining the standard with the MiSeq i100, including and expanding on innovations, including the NovaSeq X, and enabling new capabilities on the platform. Our design and manufacturing improvements were driven by the need to keep the flexibility and broad utility that the MiSeq offers today, while unlocking the value for customers beyond cost per gigabase, with a focus on speed, simplicity, scale, and quality, and most importantly, improved user experience. Emmanuel described some of the high-level customer benefits these new capabilities provide.
I want to take a few minutes to go deeper into some of the technical innovations behind revolutionizing the instrument that enables complete solutions for everyone in every lab, everywhere. Building on the technology first launched with the iSeq, we developed a higher density, CMOS-based surface imaging technology that captures and detects nucleotide incorporations within the flow cell. Leveraging the latest innovations in the imaging industry, the new CMOS-based detection technology enables higher pixel density and larger sensors, radically reduces integration times, eliminates collection optics, and replaces lasers with LED excitation sources. Together, these innovations significantly reduce the size and complexity of the instrument, while enabling up to four times the output and four times faster turnaround time than the MiSeq.
We've taken the complexity out of the instrument and engineered an integrated cartridge technology with co-located microfluidics and imaging sensors, pressurized fluidics, zero dead volume microvalves, and the MiSeq i100 offers a simpler, faster, and more intuitive user experience. We've also engineered sustainability into design with easily recyclable components. For the first time in the sequencing industry, our advancements in chemistry stabilization, lyophilization, and novel manufacturing processes have led to pioneering the world's first dry microsphere reagents that can ship and store at ambient temperatures and are guaranteed shelf stable for up to three months at room temperature. As a sustainability leader in our industry, we've enabled 85% reduction in packaging weight, reducing CO2 emissions, and helping customers meet industrial and regional targets. The MiSeq i100 doesn't just include the new XLEAP-SBS chemistry we introduced with the NovaSeq X, it improves on it.
We've radically improved its chemical components to deliver some of the fastest sequencing runs on the market today. Using new fluorescent dyes, optimized for photostability and ambient storage, the MiSeq i100 enables two to three times faster turnaround time and five hundred times more stability than its predecessor. All of these innovations together bring you the fastest instrument in its class, capable of a hundred-cycle pathogen detection test in less than four hours, or a three hundred-cycle oncology panel in less than eight hours. The revolutionized XLEAP-SBS chemistry, novel architecture, and innovative cartridge technology provide a longer read lengths with dramatically improved accuracy throughout the whole read. As you can see from the graph, the data quality at the end of the reads is dramatically improved. For Read 1, it's more than one point five times better, and for Read 2, it's more than eight point five times better.
The MiSeq i100 is more than just a sequencer, it is a demonstration of Illumina's commitment to launch total systems with complete workflows. The integrated menu of eighteen complete workflows simplifies sample-to-answer insights and data analysis across the broad range of biological applications. It's not just a system, it's a solution. Simplified workflows and the enhanced user interface make the MiSeq i100 extremely easy to operate. Customers can install the instrument themselves and connect to the network right out of the box. Our design team focused on delivering load-and-go consumables with one-touch programming. The most important information that you care about when your run is done, data quality, and total output is available at your fingertips. In the decade plus since we first launched the MiSeq, we've revolutionized genomics to help mature nascent technology into a standard tool used in science and medicine.
The MiSeq i100 system led to more than 140 invention disclosures and 60-plus patent families. Once again, we've redefined the standard for benchtop sequencing, creating new capabilities to deliver speed, simplicity, scalability, and quality with a world-class user experience. We believe the MiSeq i100 will provide a powerful new tool to help our customers achieve their goals and fulfill their ambitions. Back to you, Everett.
Thank you, Steve. Now that we've introduced you to the MiSeq i100 and the innovative breakthrough it took to develop, let's put it to work. Next, Ali Crawford, Senior Director of Scientific Research at Illumina, will share data generated on the instrument. Ali, take it away.
Thank you, Everett. For the first time ever, we are offering an extensive menu of applications directly on the instrument. 18 workflows consisting of library prep kits, pre-designed panels, and DRAGEN analysis applications, allowing you to fully benefit from the power of sequencing. Let's look at a few examples highlighting the data quality for some of these workflows, beginning with oncology. Next-generation sequencing has revolutionized our understanding of the many complexities of cancer genomes by identifying key mutations such as gene fusions, copy number alterations, and other genomic aberrations that underlie tumorigenesis. With oncology applications, it is so important to generate high-quality data and get answers quickly. For this demonstration, we started with reference cell line DNA and generated libraries using the Pillar OncoReveal Myeloid Panel. Sequencing data from the MiSeq i100 was analyzed with DRAGEN Amplicon and then visualized with Illumina Connected Insights.
The Pillar OncoReveal Myeloid Panel targets 58 genes with as little as 10 nanograms of DNA input. The assay utilizes Pillar's proprietary SLIMamp technology, which enables a simple, single-tube target enrichment workflow. With Pillar's OncoReveal kitted assay panels, users can go from DNA to loading the MiSeq i100 within a single shift. The result is high-quality sequencing data with greater than 95% Q30 bases and over 25 million reads in a 7-hour run. Using Illumina Connected Insights to visualize the data, expected variants, such as this missense change in the FLT3 gene, were accurately detected and are ready for additional interpretation and reporting. The MiSeq i100 is able to reliably detect somatic variants with high accuracy. With the MiSeq i100, powered by XLEAP-SBS and rapid processing by DRAGEN Amplicon, you'll have accurate results for your oncology applications within 24 hours. Let's look at another example.
NGS offers accurate detection, genotyping, and genome sequencing of viruses and pathogens using targeted solutions. With its fast run times, user-friendly onboard analysis, and flexible throughput, the MiSeq i100 is ideally suited for infectious disease surveillance and identification. Here, we have used the Illumina Microbial Amplicon Prep for Influenza A/B, also known as IMAP Flu, to amplify the whole genome of influenza viruses in reference samples containing different strains of influenza. Libraries were then sequenced on the MiSeq i100 and analyzed by the DRAGEN Targeted Microbial App. The IMAP Flu kit supports flexible inputs, including RNA extracted from nasal swabs or other relevant samples with varying levels of viral load. The results include coverage across all eight segments of the influenza virus genome, including those of the avian subtypes, such as H5N1, enabling accurate viral characterization and tracking.
Results generated with the MiSeq i100 show effective influenza virus genome sequencing at a sufficient medium depth for strain-level identification and mutational analysis across a range of viral loads. Rapid identification and genomic characterization of pathogens is important for surveillance, to monitor disease spread, and inform public health responses. The MiSeq i100 Series has multiple reagent kits available, supporting a wide range of throughputs, so you can efficiently sequence smaller sample sizes or batch samples quickly, getting answers faster than ever before. Let's take this one step further and look at a real-world example. Wastewater-based surveillance can be utilized to track the presence of disease-causing pathogens at a community level. Detection of viruses in wastewater can serve as an early warning that a particular virus is spreading within a community. For such applications, rapid turnaround time and support for low sample inputs are critical.
Here, we used one of the workflows on the MiSeq i100 Series. This workflow is paired with the Illumina Viral Surveillance Panel, also known as VSPv2, and the DRAGEN Microbial Enrichment Plus App for analysis. The data analysis begins automatically, and a data summary is provided directly on the instrument within hours after sequencing is complete. The Illumina VSPv2 targets over 200 viruses and subtypes, including influenza and SARS-CoV-2, and can support as low as 10-nanogram inputs, making it an ideal surveillance tool for public health programs. In this example, we generated libraries with a VSPv2 using wastewater samples collected near Madison, Wisconsin, at six different time points over a two-month period. This graph shows the abundance of the top respiratory and gastrointestinal viruses detected over a six-week period as a heat map, with blue depicting low presence and red highlighting higher viral abundance.
These results highlight multi-pathogen surveillance capabilities of one of Illumina's easy-to-use workflows on the MiSeq i100 Series and its application to capture the variability of pathogen genomic information at a community level. You can simplify data analysis by eliminating the need for bioinformatics expertise and helping unlock sequencing capabilities to decentralize pathogen surveillance and protect the health of our communities. The MiSeq i100 Series is suitable for many applications, from oncology research to infectious disease testing to community surveillance. As you can see, no matter what your research, the solution will provide you with high quality and accurate results that you can trust. I know some of you can't use NGS today, but with the ease of use of MiSeq i100 Series, now you can.
Thanks, Ali. The MiSeq i100 Series is set to make an impact across so many areas of genomic sequencing. I can't wait to see what scientists will do with this new instrument. So far, the MiSeq i100 has already made a big impression with early testers. Before we go any further today, let's hear from a couple more customers and hear their thoughts on the instrument.
So for us, this instrument will have such a big impact on our microbial profiling and plasmid sequencing services. It's going to enable faster sequencing at a lower cost, but also really high-quality data that's to be generated from the system. We're really excited to see how that will work. The fact that it's got onboard DRAGEN will mean that we'll be able to do integrated analysis at some point. With our plasmid services, most of our clients require really rapid plasmid sequencing for their respective services or applications that they're looking at. And with having a system that is so quick, it means we'll really be able to deliver data within a very tight timeframe, which will make things easier for us, but also more accessible for our clients.
So we're all really excited to see how this will work in those two spaces.
Most of the sequencing operation at the Centre d'expertise of Génome Québec are on the NovaSeq X Plus, which mean we have to gather together a lot of projects or samples to be able to start a run that generates a lot of data. With this new instrument that generates less data in a quicker time, we are able to provide answers quickly for small project or researchers that need fast answers. My reaction when I found out that the reagents are sent and being stored at room temperature, I was delighted. I mean, I've been waiting for this for years.
Receive an Illumina order of lots of sequencing kit takes a lot of times in the lab, so we can save on packing time and on waste that we generate in the lab, and it really helps the planning for the sequencing run. We don't have to take two days before to get a kit out of the freezer, so it really is a game changer to have kits stored at room temperature.
The fact that we don't need to thaw reagents anymore means that we can get runs on quicker throughout the day. It means that if we had any last-minute priorities, we don't have to wait two to three hours for a MiSeq cartridge to thaw, like, with the MiSeq system. Means we can just immediately open the box up and get a sequencing run on. It means for us, in terms of planning, it's easier for us to plan as well because we don't have to worry about any of those kinds of other factors that come with having a frozen cartridge.
I would definitely recommend this new instrument, especially for teams that has small to no experience in sequencing, because it is really easy to use, and I think for first-time user, it is really a great instrument. It is easy to use, and it give you quick answer. I think it is really a nice instrument to have in your lab.
The run times with this instrument are just fantastic. For me, personally, when I used to run a MiSeq, it would take, you know, three to four days to get a run finished, and it was a lot of stress because you just watch the clock tick on that system. So it meant that you were quite limited with what you could actually achieve in the lab. With this new system, it means that we can essentially put a run on every single day and generate high-quality data every single day, so that's quite a massive improvement from our perspective.
We love hearing directly from our customers. Your insights and feedback drive everything that we do here at Illumina, including the development of the MiSeq i100 Series. You asked us to make sequencing faster, to make it simpler, all while delivering high-quality data in a more sustainable way, and we listened. Today, we're extremely proud to bring you the MiSeq i100 Series. We hope it's going to meet and exceed all of your expectations, revolutionizing sequencing around the world yet again. Before we end, I wanna invite you to come see this new technology for yourself. We have dozens of upcoming events across the world over the next several months, so you can experience the MiSeq i100 in a city near you. A full list of conferences, regional events, and demonstrations at our solutions centers will be available on our website.
Just follow the link at the end of today's event. If you can't make one of those events, and you'd like more information about the instrument, we invite you to visit our website or reach out to your sales representative. The advanced simplicity of MiSeq i100 delivers more possibilities to every lab, empowering you to sequence with more applications and discovery power. But even with this unprecedented level of ease and efficiency, we understand making the leap to something new might feel a bit daunting. The good news is Illumina is always here to help. If you need a hand, our global support team is available to help get you the answers right away. We've created this sequencing solution for you and built this technology to help you push genetics forward. With MiSeq i100 Series, what barriers will you break? What kind of discoveries await?
This is an exciting time for all of us, and we can't wait to see what you'll do next. Have a wonderful day, and thanks again for joining us.